KR900013949A - 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 - Google Patents
정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 Download PDFInfo
- Publication number
- KR900013949A KR900013949A KR1019900002912A KR900002912A KR900013949A KR 900013949 A KR900013949 A KR 900013949A KR 1019900002912 A KR1019900002912 A KR 1019900002912A KR 900002912 A KR900002912 A KR 900002912A KR 900013949 A KR900013949 A KR 900013949A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- tetrahydro
- cis
- naphthalene amine
- dichlorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (11)
- 정신병치료, 소염 또는 면역억제 효과량의 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 산부가 염을 정신병치료, 소염 또는 면역억제를 필요로 하는 포유동물에게 투여함을 포함하는, 상기 포유동물에서 정신병치료, 소염 또는 면역억제 효과를 얻는 방법 :상기식에서, R1은 수소 및 C1내지 C3알킬로 구성된 그룹중에서 선택되고, R2는 C1내지 C3알킬이고, Z는(여기에서, X와 Y는 각각 독립적으로 수소, 플루오로, 크로로, 브로모, 트리플루오로메틸, C1내지 C3의 알콕시 및 시아노로 구성된 그룹중에서 선택되고, X와 Y중 적어도 하나는 수소가 아니다)이고, W는 수소, 플루오로, 클로로, 브로모, 트리플루오로메틸 및 C1내지 C3의 알콕시로 구성된 그룹중에서 선택된다.
- 제1항에 있어서, 상기 화합물이 시스 또는 트란스 이성체인 방법.
- 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-4-(4-클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3-트리플루오로메틸, 4-클로로-페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 트란스-(1S) (1R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 트란스-(1S) (4S)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 시스-(1S) (4R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-아미노-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N,N-디메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
- 정신병치료, 소염 또는 면역억제 효과량의 제1항의 화합물과 약학적으로 허용되는 담체를 함체 포함하는 정신병 및 염증치료와 면역억제 유도를 위한 약학 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US320,014 | 1989-03-07 | ||
US07/320,014 US4981870A (en) | 1989-03-07 | 1989-03-07 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
US320.014 | 1989-03-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900013949A true KR900013949A (ko) | 1990-10-22 |
KR920005810B1 KR920005810B1 (ko) | 1992-07-20 |
Family
ID=23244506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900002912A KR920005810B1 (ko) | 1989-03-07 | 1990-03-06 | 정신병 치료제 |
Country Status (17)
Country | Link |
---|---|
US (2) | US4981870A (ko) |
EP (1) | EP0386997B1 (ko) |
JP (2) | JPH0714870B2 (ko) |
KR (1) | KR920005810B1 (ko) |
AT (1) | ATE150299T1 (ko) |
AU (1) | AU610036B2 (ko) |
CA (1) | CA2011428C (ko) |
DE (1) | DE69030212T2 (ko) |
DK (1) | DK0386997T3 (ko) |
HU (1) | HU221624B1 (ko) |
IE (1) | IE81047B1 (ko) |
IL (1) | IL93576A (ko) |
MY (1) | MY106272A (ko) |
NZ (1) | NZ232800A (ko) |
PH (1) | PH26542A (ko) |
PT (1) | PT93351B (ko) |
ZA (1) | ZA901743B (ko) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
WO1991009594A1 (en) * | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
ES2060547B1 (es) * | 1992-06-04 | 1995-06-16 | Ferrer Int | Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina". |
ZA944513B (en) * | 1993-06-23 | 1996-01-16 | Cambridge Neuroscience Inc | Sigma receptor ligands |
ES2074946B1 (es) * | 1993-07-19 | 1996-06-16 | Ferrer Int | Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. |
US20030133974A1 (en) * | 1997-07-01 | 2003-07-17 | Curatolo William John | Encapsulated solution dosage forms of sertraline |
WO1999001121A1 (en) | 1997-07-01 | 1999-01-14 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
CA2395231C (en) | 1999-12-23 | 2006-08-15 | Pfizer Products Inc. | Hydrogel-driven layered drug dosage form |
DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
US6988556B2 (en) * | 2002-02-19 | 2006-01-24 | Halliburton Energy Services, Inc. | Deep set safety valve |
US7087785B2 (en) | 2002-09-16 | 2006-08-08 | Sepracor Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
EP1545485A2 (en) * | 2002-09-16 | 2005-06-29 | Sepracor Inc. | Treatment of cns disorders with trans-4- (3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
RU2361862C2 (ru) * | 2003-12-29 | 2009-07-20 | Сепракор Инк. | Пиррольные и пиразольные ингибиторы daao |
CN103259027A (zh) | 2005-04-28 | 2013-08-21 | 普罗透斯数字保健公司 | 药物信息系统 |
CA2614282A1 (en) * | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
KR101294014B1 (ko) | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
US8053603B2 (en) * | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
PT2816024T (pt) * | 2006-03-31 | 2017-10-20 | Sunovion Pharmaceuticals Inc | Aminas quirais |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
RU2008152404A (ru) * | 2006-05-31 | 2010-07-10 | Сепракор Инк. (Us) | Лечение болевых расстройств транс 4-(3, 4-дихлорфенил)-1, 2, 3, 4-тетрагидро-1-нафталинамином и его формамидом |
US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
KR20090071598A (ko) | 2006-09-18 | 2009-07-01 | 랩터 파마슈티컬 인코포레이티드 | 수용체 결합 단백질(rap)-접합체 투여에 의한 간 질환의 치료 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
US20090099248A1 (en) * | 2007-01-18 | 2009-04-16 | Sepracor Inc. | Inhibitors of d-amino acid oxidase |
US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
RU2470011C2 (ru) | 2007-05-31 | 2012-12-20 | Сепракор Инк. | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов |
US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
TWI556839B (zh) | 2009-05-06 | 2016-11-11 | 研究室護膚股份有限公司 | 包含活性劑-磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法 |
US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
DK2968220T3 (da) | 2013-03-15 | 2021-06-14 | Agenebio Inc | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
KR20170003677A (ko) * | 2014-05-13 | 2017-01-09 | 선오비온 파마슈티컬스 인코포레이티드 | Adhd의 치료를 위한 다소트랄린의 방법 및 조성물 |
CA2948839A1 (en) * | 2014-05-13 | 2015-11-19 | Sunovion Pharmaceuticals Inc. | Dosage of dasotraline and method for treatment of adhd |
WO2016046669A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of depression and neurological diseases |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
FR3071726B1 (fr) * | 2017-09-29 | 2020-09-04 | Univ Paris Sud | Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1420472A (en) * | 1972-09-27 | 1976-01-07 | Pfizer | Aminophenyltetralin compounds |
JPS59497B2 (ja) * | 1979-11-01 | 1984-01-07 | フアイザ−・インコ−ポレ−テツド | トランス−4−フエニル−1,2,3,4−テトラヒドロ−1−ナフタレンアミンの抗抑うつ性誘導体 |
US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
-
1989
- 1989-03-07 US US07/320,014 patent/US4981870A/en not_active Expired - Lifetime
-
1990
- 1990-02-28 IL IL9357690A patent/IL93576A/en not_active IP Right Cessation
- 1990-03-05 MY MYPI90000347A patent/MY106272A/en unknown
- 1990-03-05 CA CA002011428A patent/CA2011428C/en not_active Expired - Fee Related
- 1990-03-06 HU HU9001325A patent/HU221624B1/hu not_active IP Right Cessation
- 1990-03-06 AT AT90302365T patent/ATE150299T1/de not_active IP Right Cessation
- 1990-03-06 JP JP2054802A patent/JPH0714870B2/ja not_active Expired - Fee Related
- 1990-03-06 EP EP90302365A patent/EP0386997B1/en not_active Expired - Lifetime
- 1990-03-06 PT PT93351A patent/PT93351B/pt not_active IP Right Cessation
- 1990-03-06 AU AU50796/90A patent/AU610036B2/en not_active Ceased
- 1990-03-06 DE DE69030212T patent/DE69030212T2/de not_active Expired - Fee Related
- 1990-03-06 DK DK90302365.3T patent/DK0386997T3/da active
- 1990-03-06 NZ NZ232800A patent/NZ232800A/en unknown
- 1990-03-06 KR KR1019900002912A patent/KR920005810B1/ko not_active IP Right Cessation
- 1990-03-07 IE IE79890A patent/IE81047B1/en not_active IP Right Cessation
- 1990-03-07 PH PH40157A patent/PH26542A/en unknown
- 1990-03-07 ZA ZA901743A patent/ZA901743B/xx unknown
- 1990-12-05 US US07/622,308 patent/US5061728A/en not_active Expired - Lifetime
-
1994
- 1994-07-25 JP JP6172929A patent/JP3020808B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69030212T2 (de) | 1997-06-26 |
EP0386997B1 (en) | 1997-03-19 |
ZA901743B (en) | 1991-10-30 |
PH26542A (en) | 1992-08-19 |
MY106272A (en) | 1995-04-29 |
IE900798L (en) | 1990-09-07 |
EP0386997A2 (en) | 1990-09-12 |
AU5079690A (en) | 1990-09-20 |
JPH07173056A (ja) | 1995-07-11 |
JPH02300121A (ja) | 1990-12-12 |
HU901325D0 (en) | 1990-05-28 |
AU610036B2 (en) | 1991-05-09 |
JP3020808B2 (ja) | 2000-03-15 |
IL93576A (en) | 1995-12-08 |
US5061728A (en) | 1991-10-29 |
CA2011428C (en) | 1994-11-08 |
DE69030212D1 (de) | 1997-04-24 |
PT93351B (pt) | 1996-03-29 |
US4981870A (en) | 1991-01-01 |
NZ232800A (en) | 1997-07-27 |
JPH0714870B2 (ja) | 1995-02-22 |
ATE150299T1 (de) | 1997-04-15 |
IL93576A0 (en) | 1990-11-29 |
PT93351A (pt) | 1990-11-07 |
IE81047B1 (en) | 1999-12-01 |
KR920005810B1 (ko) | 1992-07-20 |
HU221624B1 (hu) | 2002-12-28 |
HUT59000A (en) | 1992-04-28 |
EP0386997A3 (en) | 1992-04-29 |
DK0386997T3 (da) | 1997-04-14 |
CA2011428A1 (en) | 1990-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900013949A (ko) | 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 | |
KR910004572A (ko) | 아자비시클로 퀴놀론 카르복실산 | |
IL61374A0 (en) | Derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions containing them | |
KR950031074A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
KR930019655A (ko) | 종양치료 조성물 및 치료방법 | |
ES8201948A1 (es) | Un procedimiento para la preparacion de nuevos derivados transisomericos de 4-fenil-1,2,3,4- tetrahidro-1-naftalenamina. | |
KR880012218A (ko) | 캘폰 유도체를 사용한 다발성 경화증의 치료방법 | |
DK0722313T3 (da) | Viskoelastiske sammensætninger af fluorerede organiske forbindelser | |
ECSP034815A (es) | "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas" | |
PE20050130A1 (es) | Compuestos organicos | |
AR018732A1 (es) | Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene. | |
CO5560559A2 (es) | Formulacion de suspension oral estabilizada | |
BR9610350A (pt) | Tratamentos contra piolhos e misturas, loções e lìquidos para pulverização, repelentes de insetos. | |
DK1127571T3 (da) | Anvendelse af sertralin til at behandle posttraumatisk stresssygdom | |
AR012426A1 (es) | Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida. | |
PE20081781A1 (es) | Agonistas de adrenoreceptores alfa2c funcionalmente selectivos | |
KR940005274A (ko) | 쇼그렌(Sjoegren)증후군 치료제 | |
KR950016723A (ko) | 자가면역 질병의 억제 방법 | |
ATE209177T1 (de) | Von einem aromatischen oder heteroaromatischen radikal substituierte biphenylderivate und diese enthaltende pharmaceutische und kosmetische compositionen | |
KR930005972A (ko) | N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민 | |
AR033426A1 (es) | Uso de compuestos carbamatos en la prevencion o el tratamiento de trastornos de movimiento | |
KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
RU98106625A (ru) | Производные колхицина и тиоколхицина, обладающие противовоспалительной и миорелаксирующей активностями | |
AR032653A1 (es) | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. | |
KR950701623A (ko) | 치환된 헥사하이드로벤조페난트리딘 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20040701 Year of fee payment: 13 |
|
LAPS | Lapse due to unpaid annual fee |